FDA fast track designation enables increased regulatory interaction and potential rolling BLA review for RPTR-1.201 in ...
TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers. The company had ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results